Vibrio anguillarum bacteriophage VIB-ANP-1 and use thereof for inhibiting proliferation of Vibrio anguillarum bacteria
Inventors
Yoon, Seong Jun • JUN, Soo Youn • KWON, An Sung • Hwang, Soon Hye • Song, Hyun Min • Jung, Ji In • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11439677-B2
Publication Date
2022-09-13
Expiration Date
Abstract
The present invention relates to Siphoviridae bacteriophage Vib-ANP-1(accession number KCTC 13075BP) having the ability to specifically kill Vibrio anguillarum bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention or treatment of Vibrio anguillarum bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.
Core Innovation
The patent describes a Siphoviridae bacteriophage Vib-ANP-1 deposited as accession number KCTC 13075BP, having a 213.97 kb genome expressed by the nucleotide sequence of SEQ ID NO:1. Vib-ANP-1 has specific antibacterial activity against Vibrio anguillarum and is described as specifically killing Vibrio anguillarum while not killing several non-target bacteria.
The patent addresses vibriosis caused by Vibrio anguillarum and positions the phage as an alternative to conventional approaches for controlling the disease. It further describes use of Vib-ANP-1 in compositions formulated with maltodextrin.
A feed additive composition is provided that includes maltodextrin and Vib-ANP-1 at specified titers. The patent also describes a method for suppressing diseases caused by Vibrio anguillarum or alleviating the pathological condition of those diseases by administering the composition to an animal other than a human.
Claims Coverage
The document provides two independent claims centered on a specific phage identity, a defined genome size/sequence reference, defined dosing ranges, and functional disease suppression as the outcome.
Maltodextrin feed additive with Vib-ANP-1 at specified titer range and defined genome
A feed additive composition comprising maltodextrin and 1×10^4 pfu/ml to 1×10^15 pfu/ml or 1×10^4 pfu/g to 1×10^15 pfu/g of Siphoviridae bacteriophage Vib-ANP-1 that has specific antibacterial activity against Vibrio anguillarum and a 213.97 kb size of genome expressed by a nucleotide sequence of SEQ ID NO:1, and is deposited as accession number KCTC 13075BP.
Administering Vib-ANP-1 maltodextrin composition to non-human animal for disease suppression
A method for suppressing diseases caused by Vibrio anguillarum, or alleviating the pathological condition of the diseases caused by Vibrio anguillarum, comprising administering to an animal other than a human a composition comprising maltodextrin and 1×10^4 pfu/ml to 1×10^15 pfu/ml or 1×10^4 pfu/g to 1×10^15 pfu/g of Siphoviridae bacteriophage Vib-ANP-1 (Accession number: KCTC 13075BP) with specific antibacterial activity against Vibrio anguillarum and a 213.97 kb size of genome encoded by the nucleotide sequence of SEQ ID NO:1.
Across both independent claims, the core coverage requires a maltodextrin-based composition containing Siphoviridae bacteriophage Vib-ANP-1, defined titers within specified ranges in pfu/ml or pfu/g, and specific antibacterial activity against Vibrio anguillarum tied to the 213.97 kb genome reference (SEQ ID NO:1) for the deposited phage (KCTC 13075BP). The method claim further requires administering the composition to an animal other than a human to suppress disease or alleviate pathological condition.
Stated Advantages
Specific antibacterial activity against Vibrio anguillarum.
Suppresses diseases caused by Vibrio anguillarum or alleviates the pathological condition of those diseases.
Targeted killing with described non-target protection against several non-target bacteria.
Documented Applications
Feed additive use comprising maltodextrin and Vib-ANP-1 for suppressing diseases caused by Vibrio anguillarum or alleviating pathological conditions in an animal other than a human.
Interested in licensing this patent?